2026 ASCO Breast Cancer Highlights: Triple Negative Breast Cancer - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

2026 ASCO Breast Cancer Highlights: Triple Negative Breast Cancer

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new antibody drug conjugate treatment options in first line triple negative breast cancer.

  • October 15, 2026

Share

Objective:

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new antibody-drug conjugate treatment options for first-line triple-negative breast cancer.

Interpretation:

The provided context identifies the topic and speakers but includes no transcript details or study findings.

Limitations:
  • No video transcript, study data, or source URL was provided.

Original Source(s)

2026 ASCO Breast Cancer Highlights: Triple Negative Breast Cancer

  • October 15, 2026

Related Content

Spinal ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes with a focus on the pediatric population (Part III of ependymomas across compartments)

2026 ASCO Breast Cancer Highlights: PANKU-Breast02

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new results from the PANKU-Breast02 Study on a new dual-antibody drug conjugate, called izalontamab brengitecan (iza-bren), for metastatic triple-negative breast cancer.

  • October 15, 2026

  • 1 min
2026 ASCO Breast Cancer Highlights: BWEL

Harold Burstein, MD, PhD, and Jennifer A. Ligibel, MD discuss new research from the Breast Cancer Weight Loss (BWEL) trial, as well as recommendations for lifestyle, diet and GLP1 agonists.

  • October 15, 2026

  • 1 min